Results 61 to 70 of about 12,086 (222)

Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice [PDF]

, 2013
Tissue plasminogen activator (tPA) is the only FDA-approved treatment for reperfusing ischemic strokes. But widespread use of tPA is still limited by fears of inadvertently administering tPA in patients with intracerebral hemorrhage (ICH).
Emiri Mandeville, Cianchetti, Flor A., Ken Arai, van Leyen, Klaus, Frieder Schlunk (280822), Eng H. Lo (112154), Kazim Yigitkanli, Chris B Schaffer, Mandeville, Emiri, Yigitkanli, Kazim, Xiaoying Wang, Nathanael L Rosidi, Chris B. Schaffer (155846), Arne Lauer (280824), Fan, Xiang, Eng H Lo, Helmuth Steinmetz (149409), Rosidi, Nathanael L., Xiang Fan (280830), Schlunk, Frieder, Frieder Schlunk, Flor A. Cianchetti (280825), Wang, Xiaoying, Christian Foerch (149410), Flor A Cianchetti, Kazim Yigitkanli (280829), Arai, Ken, Förch, Christian, Leyen, Klaus van, Lo, Eng H., Foerch, Christian, Xiang Fan, Schaffer, Chris B., Ken Arai (280828), Klaus van Leyen, Helmuth Steinmetz, Emiri Mandeville (280827), Steinmetz, Helmuth, Christian Foerch, Lo, Eng, Arne Lauer, Nathanael L. Rosidi (280821), Xiaoying Wang (30853), Klaus van Leyen (280831), Lauer, Arne   +44 more
core   +1 more source

In Silico docking studies on thrombolytic properties ofHomoeopathic Medicine Cactus grandiflorus by activationof tissue-Plasminogen Activator in the treatment of Vascular Thrombosis [PDF]

, 2023
Vascular thrombosis is a life-threatening condition caused by the formation of blood clots in the blood vessels. Thrombolytic therapy is a commonly used treatment for this condition.
M Vinoth, G Senthil Kumaran, N Rajalskhmi   +2 more
core   +1 more source

SUCCESSFUL ASPIRATION OF THROMBOTIC MASSES OUT OF THE LEFT INTERNAL CAROTID ARTERY LUMEN USING A PROXIMAL EMBOLIC PROTECTION DEVICE IN THE CONDITIONS OF THROMBOLYTIC THERAPY PERFORMANCE

Инновационная медицина Кубани, 2019
Combined techniques of treatment for ischemic stroke are even more often included into routine work of specialized teams. One of them based on a combination of systemic thrombolytic therapy and endovascular methods is characterized by a high rate of ...
A. S. Nekrasov, A. I. Beliy, O. S. Volkolup, P. A. Tupikin   +3 more
doaj   +2 more sources

Drug‐Coated Balloon‐Based Strategy for De Novo Coronary Artery Disease Across Complex and High‐Risk Indicated Percutaneous Coronary Intervention Risk Categories: A Multicenter Registry Study

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Evidence regarding the risk‐stratified effectiveness of drug‐coated balloon (DCB)‐based PCI for de novo coronary artery disease (CAD) remains limited, particularly in patients undergoing complex and high‐risk indicated percutaneous coronary intervention (CHIP PCI).
Dong Oh Kang, Sunwon Kim, Ae‐Young Her, Eun‐Seok Shin   +3 more
wiley   +1 more source

Barriers of Thrombolysis Therapy in Developing Countries

Stroke Research and Treatment, 2011
The developing world carries the highest burden of stroke mortality and stroke-related disability. The number of stroke patients receiving r-tPA in the developing world is extremely low.
Kavian Ghandehari
doaj   +1 more source

Current strategies to enhance the target efficiency of advanced multifunctional ultrasound contrast agents in ischemic diseases

Interdisciplinary Medicine, EarlyView.
The graphical abstract outlines a novel multifunctional ultrasound contrast agent for the diagnosis and treatment of ischemic diseases, along with innovative strategies to enhance its targeting efficiency. Abstract Ischemic diseases, such as myocardial infarction, stroke, and peripheral ischemia, are leading causes of death and disability worldwide ...
Yangyang Zhou, Jing Lin, Yu Chen, Jiaqi Zhao   +3 more
wiley   +1 more source

Pharmacological modification of the vascular response to systemically administered thrombolytic enzymes (CA-7) [PDF]

, 1969
Thrombolytic enzymes are recognized as potent activators of the vasodepressor plasma kinins. In an attempt to modify the vascular response to systemic administration of such enzymes, the fungal protease CA-7 was used as a model.
Sandra L. Miller, Harvey J. Freedman, Walter H. E. Roschlau   +2 more
core   +1 more source

Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke

Drug Delivery, 2021
Ischemic stroke is one of the major causes of severe disability and death worldwide. It is mainly caused by a sudden reduction in cerebral blood flow due to obstruction of the supplying vessel by thrombi and subsequent initiation of a complex cascade of ...
Hongyin Ma, Zhenmin Jiang, Jiayun Xu, Junqiu Liu, Zhen-Ni Guo   +4 more
doaj   +1 more source

Thrombolytics, Anticoagulants, and Antiplatelet Agents [PDF]

Stroke, 2006
More than 250 articles regarding thrombolytic therapy in acute ischemic stroke were published in the first 10 months of 2005 (Source PubMed). In this section we will focus on some reports that directly affect and improve the treatment of stroke patients, that led to further phase III trials, or that represent a great disappointment after several years ...
openaire   +2 more sources

Intelligent design of artificial biocatalyst for biomedical diseases

Journal of Intelligent Medicine, EarlyView.
This review summarizes recent advances in the intelligent design of artificial biocatalysts for biomedical diseases. By leveraging tailored design strategies, including environment‐responsive engineering and rational/artificial intelligence‐aided optimization, these biocatalysts enable precise modulation of pathological microenvironments and targeted ...
Lijie Zhang, Nan Song, Huanhuan Qiao, Si Sun   +3 more
wiley   +1 more source